The pharmaceutical industry spends an average of $2.23 billion to bring a single new molecular entity to market, yet the infrastructure supporting drug development remains anchored to legacy processes built around document generation rather than data intelligence. Every day of launch delay costs up to $800,000 in lost prescription sales, rising to $1.4 million in high-value therapeutic areas. The root cause is not a lack of data, but a structural execution gap: the distance between what pharmaceutical portfolio management tools report and what is actually happening across labs, manufacturing suites, and CRDMO networks.
That gap is sustained by a “paper barrier” that pervades sponsor-CRDMO collaboration. Technology transfer remains an 18-to-30-month process costing over $5 million per occurrence. QA teams spend more than 70% of their time manually reviewing batch records. Human data entry error rates in clinical and laboratory environments run between 1% and 5%. These inefficiencies compound across every phase of the portfolio lifecycle, eroding NPV and delaying patient access to therapies.
Closing the execution gap requires a unified data orchestration architecture where process data flows continuously from the point of execution into the portfolio layer, where deviations surface as leading signals before they become incidents, and where agentic AI is grounded in governed, organization-specific data rather than general knowledge. This is the architectural and behavioral shift that moves pharmaceutical organizations from AI-ready to AI-actionable.
This white paper, co-authored by L7 Informatics President and CEO Vasu Rangadass and Turnberry Solutions Managing Partner Emily Anderson, quantifies the cost of fragmentation, maps the ROI of digital continuity, and outlines the operational and behavioral changes required to translate better data into better decisions at portfolio scale.
To access this resource, please make sure to accept cookies.